Ian is a globally experienced industry leader with over 25 years in the pharmaceutical and life sciences sectors. Throughout his distinguished career, he has held senior and executive leadership roles across several prominent organizations, including Quintiles/IQVIA, Clinerion, Aetion, and TriNetX. Most recently, Ian served as Chief Commercial Officer and General Manager Pharma at CENTOGENE, where he played a key role in advancing clinical development in the area of genetic diagnostics and real-world evidence generation for rare diseases.

At CENTOGENE, Ian led initiatives to build one of the world’s largest genomic databases for rare diseases—integrating genetic sequencing, bioinformatics, and clinical insights to develop precision diagnostic tools. His work helped position the company as a trusted partner to pharmaceutical companies, healthcare providers, and research institutions around the globe.

‍

“I am passionate about advancing medicine and leveraging real-world data to improve patient outcomes, especially for individuals living with rare and often undiagnosed genetic conditions. By using a forward-thinking approach, we can help drive the mission to offer more effective and targeted treatments to patients globally. I hold a strong belief in the transformative power of data-driven technologies and their ability to revolutionize healthcare. My vision continues to focus on creating a more personalized, data-driven future for the diagnosis and treatment of diseases worldwide,” says Ian Rentsch.

‍

Ian’s extensive expertise spans business development, strategic partnerships, global operations, and mergers and acquisitions. His deep understanding of both pharmaceutical trends and technology-driven healthcare innovation provides IOMED with valuable perspective as we continue to expand our impact and international reach.

“Welcoming Ian Rentsch to IOMED marks a new chapter in our journey. His visionary leadership, global perspective, and hands-on experience with data-enabled healthcare innovation will be instrumental in expanding our reach and advancing our mission to unlock the full potential of real-world data,” says Rohit Mistry, CEO of IOMED.

‍